# First successful protocol for desensitization to eptinezumab

## TL;DR

A 10-step desensitization protocol successfully manages hypersensitivity reactions to eptinezumab, a migraine prevention drug.

## Contribution

The first successful desensitization protocol for eptinezumab hypersensitivity is proposed and validated.

## Key findings

- Skin tests suggested non-IgE-mediated hypersensitivity to eptinezumab.
- Two patients successfully completed the 10-step desensitization protocol.
- The protocol is safe and effective for managing hypersensitivity reactions.

## Abstract

Eptinezumab is an anti‐calcitonin gene‐related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E–mediated, the team of Nice University Hospital (Nice, France) performed the eptinzeumab skin tests. A 10‐step desensitization protocol has been proposed to manage these reactions.

Two patients presenting with immediate hypersensitivity reactions underwent the eptinezumab skin test. Neither skin test was positive, suggesting a non‐immunoglobulin E–mediated mechanism. The patients then completed the desensitization protocol successfully.

This hospital‐based 10‐step desensitization protocol appears safe and effective.